SynthesisFrontiers in oncology2022
A systematic review of margin status in retroperitoneal liposarcomas: Does the R0 margin matter?
Synthesis in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Patterns of Presentation and Histopathology of Retroperitoneal Sarcoma in a South Asian Tertiary Center.Cureus · 2026Article
- Article
- Article
- Predictors of survival in dedifferentiated liposarcoma: A population-based analysis of the SEER database.Medicine · 2026Article
- Bladder sarcoma treated with radical cystectomy and adjuvant epirubicin and ifosfamide chemotherapy: a case report.Frontiers in oncology · 2026Article
- Retroperitoneal Dedifferentiated Liposarcoma With Penetrating Abscess Formation Secondary to Ileal Invasion: A Case Report.Clinical case reports · 2026Article
- Case Report: A giant dedifferentiated liposarcoma in the retroperitoneum.Frontiers in oncology · 2026Article
- Intraoperative use of high-speed Raman spectroscopy during soft tissue sarcoma resection.Scientific reports · 2025Article
- Prognostic factors in retroperitoneal liposarcoma after R0 resection: a study of age, histologic type, tumor stage, and differentiation grade.American journal of translational research · 2025Article
- Case Report: A 55 kg retroperitoneal liposarcoma.Frontiers in oncology · 2025Article
- Challenges and hope: latest research trends in the clinical treatment and prognosis of liposarcoma.Frontiers in pharmacology · 2025Review
- Surgical resection of a giant retroperitoneal dedifferentiated liposarcoma: a case report.Frontiers in surgery · 2025Article
- GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024Article
- Comprehensive treatment strategy for improving surgical resection rate of retroperitoneal sarcomas: a histology-specific approach narrative review.Frontiers in oncology · 2024Review
- Effect of pre-operative radiation therapy on surgical outcome in retroperitoneal sarcoma.Frontiers in surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retroperitoneal liposarcomas (RPLPSs) are a rare tumor group for which current guidelines recommend aggressive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.